Keyword: Merck & Co.

After batting aside efficacy questions in head and neck cancer, Merck’s Keytruda is back with a new batch of data, this time in new patients.

Big biopharma CEOs gave most or all their campaign contributions to Republicans this season, but one went full blue with his $120,000.

AZ and Merck's Lynparza has posted data in BRCA-mutated patients who've just wrapped up an initial round of chemo. And it’s entering with a bang.

China fines vaccine scandal-hit Changsheng $1.3 billion; Merck and Samsung bail on a Lantus biosim; Taiho grows VC fund to sixfold.

As a big ESMO 2018 kicks off, here are the studies we're most excited to see.

On Thursday, Merck’s Keytruda hit the scene with kidney cancer combination data that could snag it a new use months earlier than anticipated.

In a Humira patent deal with AbbVie, Fresenius Kabi will have to pay undisclosed royalties and can launch its biosim in Europe upon approval.

Merck is joining the chief digital officer parade, hiring Jim Scholefield from Nike to head up IT and digital strategy—not to mention cybersecurity.

Here is some news of note for the week.

Merck canceled its partnership with Samsung Bioepis for a Lantus biosimilar after facing hurdles with pricing and production costs.